CRISPR and Cancer

This week's clinical update includes news from Allogene Therapeutics and Graphite Bio. The U.S. Food and Drug Administration (FDA) recently granted...

In this update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer...

Resistance to chemotherapy is a major challenge in the treatment of non-small cell lung cancer. By profiling the spectrum of outcomes arising from...

This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...

Researchers at Ulsan National Institute of Science and Technology in South Korea have developed a CRISPR-Cas9-based method to eliminate tumour cells....

This week's update includes news about two gene-edited therapies for cancer. Allogene Therapeutics' ALLO-316 has been granted Fast Track Designation...

Intellia Therapeutics recently announced that the first patient had been dosed in its Phase 1/2a CRISPR trial for acute myleoid leukaemia (AML). The...

At a Danish hospital, researchers have integrated CRISPR gene editing into a clinical scale workflow for immunotherapy. Gene editing releases a brake...